Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.
Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancello G, Ghisini R, Sangalli C, Negri M, Mazza M, Iorfida M, Cardillo A, Sciandivasci A, Bianco N, De Maio AP, Milano M, Campennì GM, Sansonno L, Viale G, Morra A, Leonardi MC, Galimberti V, Veronesi P, Colleoni M. Dellapasqua S, et al. Among authors: milano m. Curr Oncol. 2021 Dec 7;28(6):5167-5178. doi: 10.3390/curroncol28060433. Curr Oncol. 2021. PMID: 34940072 Free PMC article. Clinical Trial.
Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C, Milano M, Mennitto A, Maggi C, Ferrari B, Rinaldi L, Mennitto R, Stefanetti C, Re B, Mariani G, Bianchi G, Capri G, de Braud F. Vernieri C, et al. Among authors: milano m. Breast Cancer Res Treat. 2017 Sep;165(2):365-373. doi: 10.1007/s10549-017-4336-z. Epub 2017 Jun 14. Breast Cancer Res Treat. 2017. PMID: 28616768
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F. Vernieri C, et al. Among authors: milano m. Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12. Clin Breast Cancer. 2019. PMID: 30635175
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, Cona MS, Maggi C, Ferrari B, Manoukian S, Mariani G, Bianchi G, Capri G, Rivoltini L, de Braud F. Vernieri C, et al. Among authors: milano m. Sci Rep. 2018 Jun 7;8(1):8703. doi: 10.1038/s41598-018-27075-z. Sci Rep. 2018. PMID: 29880896 Free PMC article. Clinical Trial.
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.
Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, Milano M, Stanzione B, Gargiulo P, Iacono D, Minisini AM, Mansutti M, Fasola G, De Placido S, Arpino G, Puglisi F. Bonotto M, et al. Among authors: milano m. Breast. 2017 Feb;31:114-120. doi: 10.1016/j.breast.2016.10.021. Epub 2016 Nov 9. Breast. 2017. PMID: 27837704 Free article.
Features of aggressive breast cancer.
Arpino G, Milano M, De Placido S. Arpino G, et al. Among authors: milano m. Breast. 2015 Oct;24(5):594-600. doi: 10.1016/j.breast.2015.06.001. Epub 2015 Jul 3. Breast. 2015. PMID: 26144637 Review.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Among authors: milano m. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
383 results